Get the Stockscreener App
38.85
1.60%
-0.63
After Hours:
38.85
Supernus Pharmaceuticals Inc stock is traded at $38.85, with a volume of 324.91K.
It is down -1.60% in the last 24 hours and up +4.86% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$39.48
Open:
$39.34
24h Volume:
324.91K
Relative Volume:
0.91
Market Cap:
$2.15B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
36.32
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+0.41%
1M Performance:
+4.86%
6M Performance:
+39.35%
1Y Performance:
+37.23%
1-Day Range:
$38.71
$39.53
1-Week Range:
$36.12
$40.28
52-Week Range:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
38.85 | 2.15B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Supernus wins FDA approval for Parkinson’s pump on fourth try - Yahoo Finance
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus Pharmaceuticals Inc [SUPN] Stock sold by Insider Bhatt Padmanabh P. for $0.1 million - Knox Daily
Supernus stock surges on FDA approval By Investing.com - Investing.com Canada
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease - Reuters
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease - MarketWatch
Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease - Marketscreener.com
FDA Approves Drug Pump for Parkinson's Disease - Newsmax
Supernus Announces FDA Approval of ONAPGO? (apomorphine hydrochloride) for Parkinson?s Disease - Marketscreener.com
SG Americas Securities LLC Takes $391,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7%Here's Why - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 Shares - MarketBeat
China Universal Asset Management Co. Ltd. Raises Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Pacer Advisors Inc. - MarketBeat
Supernus Pharmaceuticals exec sells $129,676 in stock By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells $129,676 in stock - Investing.com India
SUPN stock soars to 52-week high, hits $39.38 amid growth - MSN
(SUPN) Proactive Strategies - Stock Traders Daily
Supernus Announces Label Update for Non-Stimulant ADHD - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighShould You Buy? - MarketBeat
FDA approves Qelbree label update for ADHD treatment - Investing.com
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women - Marketscreener.com
FDA Approves Groundbreaking Label Update for Supernus ADHD Drug Qelbree - StockTitan
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Purdue Pharma and owners to pay $7.4 billion in settlement of lawsuits over the toll of OxyContin - MSN
Wedge Capital Management L L P NC Invests $1.93 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. Enters into Lease Agreement for Approximately 136,016 Square Feet for its New Headquarters with Advent Key West, LLC - Marketscreener.com
Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co. - Defense World
Schrödinger receives regulatory approval for Novartis collaboration - MSN
Despite the downward trend in earnings at Supernus Pharmaceuticals (NASDAQ:SUPN) the stock advances 3.1%, bringing five-year gains to 56% - Simply Wall St
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
SUPN (Supernus Pharmaceuticals) Intrinsic Value: DCF (FCF B - GuruFocus.com
(SUPN) Investment Report - Stock Traders Daily
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Has $8.90 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - Stock Traders Daily
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):